Key Highlights

  • Shares closed at A$53.58 on 18 November 2026, down 0.13% on the day and up approximately 71.46% over one year.
  • Underlying EBIT rose 11.5% to A$1,162.2 million for the year to 30 June 2026.
  • Underlying NPAT rose 19.3% to A$364.1 million, or 22.9% in constant currency.
  • The full-year Dividend rose 13.8% to 91 cents per share, fully franked.

Ramsay Health Care Limited (ASX:RHC) operates private hospitals and healthcare services in Australia, the United Kingdom and France. Its shares closed at A$53.58 on 18 November 2026, down 0.13% for the session and up approximately 71.46% over the past year. The company released its FY26 results on 27 August 2026 for the 12 months to 30 June 2026.

Latest Update

On 27 August 2026, Ramsay reported underlying EBIT of A$1,162.2 million, up 11.5%, and statutory EBIT of A$1,105.4 million. Net profit after tax attributable to shareholders was A$329.2 million, compared with A$24.0 million in FY25, while underlying NPAT rose 19.3% to A$364.1 million.

The company said its Australian transformation is building momentum, with underlying EBIT growth of 11.2% and an EBIT Margin uplift of 30 basis points. Ramsay UK and Elysium reported EBIT growth despite soft NHS volumes. A fully franked final dividend of 48.5 cents was declared, up 21.3%. The separation of Ramsay Santé is subject to a Shareholder vote in November, and Leverage in the funding group is below 2 times.

Company Background and Sector Context

Ramsay's private hospital network serves patients in Australia, the United Kingdom and France, and its funding is linked to government and private insurer arrangements. The release states that improved Revenue indexation and a focus on high-acuity care supported the Australian business.

Private hospital operators depend on elective procedure volumes, staffing and government funding frameworks. Changes in those areas can shape revenue and margins across the sector.

Ramsay's Australian hospitals and UK operations each report separately, and the company has been simplifying its structure. The release notes that Elysium, the UK business, reported EBIT growth despite lower NHS volumes. The company also stated its intention to improve cash collection and reduce Funding Group leverage below 2 times. Ramsay Santé's separation, subject to shareholder approval in November, is central to the company's simplification plan described in the release.

Risks and Uncertainties

The Ramsay Santé separation depends on shareholder approval in November, and the outcome and timing of that vote remain open. The release also refers to soft NHS volumes in the UK, which affect the Ramsay UK and Elysium business.

The release describes a focus on cash collection and free cash flow, which depends on performance initiatives that are still being implemented. Funding and labour costs remain factors for the sector.

What to Watch Ahead

Investors will watch the shareholder vote on the Ramsay Santé separation in November, progress on free Cash Flow and performance measures in the UK, and the company's leverage position in the next reporting period.

Investors will also watch the free cash flow and leverage outcomes the company has targeted for the funding group, and the response of the UK Business to NHS Volume trends in the coming reporting periods.

Taken together, the FY26 release shows higher underlying profit, a larger dividend and a simplification program under way, while statutory profit rose to A$329.2 million from A$24.0 million. The share price has risen over the past year, and the November vote and the next results will provide the next measures of the restructuring.